We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Olink Bioscience Introduces its New Plasma Biomarker Discovery Service
Product News

Olink Bioscience Introduces its New Plasma Biomarker Discovery Service

Olink Bioscience Introduces its New Plasma Biomarker Discovery Service
Product News

Olink Bioscience Introduces its New Plasma Biomarker Discovery Service


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Olink Bioscience Introduces its New Plasma Biomarker Discovery Service"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Olink Bioscience now offers a new research service, Plasma Biomarker Discovery Service. Using the multiplexed PLA® immunoassay platform, up to 74 potential cancer biomarkers are analyzed with high sensitivity in precious biobanked plasma samples, in no more than 2 µl of sample.

The Plasma Biomarker Discovery Service will help scientists in industry and academia to identify novel biomarkers and contribute to the understanding of human cancer and improved diagnosis.

"PLA has an industry leading sensitivity of multiplexed immunoassays while only consuming minute amounts of sample. Researchers can now access precious and limited biobanked serological materials and with our service find new protein biomarker signatures." says Dr Simon Fredriksson, Chief Scientific Officer at Olink Bioscience.

The PLA immunoassay technology employs two primary antibodies linked to DNA strands, which upon simultaneous and proximal binding to the target protein, will be ligated. Once ligated, they form a PCR amplicon typically detected with real-time quantitative PCR.

The assay is performed as a convenient homogeneous assay without any washing steps and is characterized by low sample consumption, high sensitivity, and multiplexing capability as recently published by Lundberg et al 2011 Jan 17, Mol Cell Proteomics PMID: 21242282.

Advertisement